Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers.

IF 1.3 4区 医学 Q3 NURSING Clinical journal of oncology nursing Pub Date : 2024-09-17 DOI:10.1188/24.CJON.483-491
Jennifer Lloyd, Nazy Zomorodian, Geeta Devgan, Julia Batten
{"title":"Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers.","authors":"Jennifer Lloyd, Nazy Zomorodian, Geeta Devgan, Julia Batten","doi":"10.1188/24.CJON.483-491","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival in patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).</p><p><strong>Objectives: </strong>This article reviews the role of oncology nurses and advanced practice providers (APPs) in administering talazoparib plus enzalutamide in patients with mCRPC.</p><p><strong>Methods: </strong>This review and hypothetical case study illustrate the role of oncology nurses and APPs in the administration of talazoparib plus enzalutamide and the management of adverse events to ensure safe and effective use in clinical practice.</p><p><strong>Findings: </strong>Oncology nurses and APPs play an important role in the dosing and administration of talazoparib plus enzalutamide and can recognize and manage adverse events in patients with HRR-deficient mCRPC.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical journal of oncology nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1188/24.CJON.483-491","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival in patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).

Objectives: This article reviews the role of oncology nurses and advanced practice providers (APPs) in administering talazoparib plus enzalutamide in patients with mCRPC.

Methods: This review and hypothetical case study illustrate the role of oncology nurses and APPs in the administration of talazoparib plus enzalutamide and the management of adverse events to ensure safe and effective use in clinical practice.

Findings: Oncology nurses and APPs play an important role in the dosing and administration of talazoparib plus enzalutamide and can recognize and manage adverse events in patients with HRR-deficient mCRPC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Talazoparib 加 Enzalutamide 用于 HRR 缺乏的 mCRPC 患者:肿瘤科护士和高级执业医师的实用实施步骤》。
背景:约四分之一的晚期前列腺癌患者存在同源重组修复(HRR)基因的改变。在一项全球性的3期研究中,talazoparib联合恩杂鲁胺可显著改善HRR缺陷转移性去势抵抗性前列腺癌(mCRPC)患者的无进展生存期:本文回顾了肿瘤科护士和高级医疗服务提供者(APP)在对mCRPC患者实施talazoparib加恩杂鲁胺治疗中的作用:这篇综述和假设性案例研究说明了肿瘤科护士和APP在使用他拉唑帕尼加恩杂鲁胺以及管理不良事件中的作用,以确保在临床实践中安全有效地使用他拉唑帕尼:研究结果:肿瘤科护士和APPs在talazoparib加恩杂鲁胺的剂量和给药过程中发挥着重要作用,并能识别和处理HRR缺陷型mCRPC患者的不良事件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.70
自引率
9.10%
发文量
127
审稿时长
6-12 weeks
期刊介绍: The Clinical Journal of Oncology Nursing (CJON) is an official publication of the Oncology Nursing Society (ONS) and is directed to the practicing nurse specializing in the care of patients with an actual or potential diagnosis of cancer. CJON is a vehicle to promote the mission of ONS, which is to advance excellence in oncology nursing and quality cancer care. The CJON mission is twofold: to provide practical information necessary to care for patients and their families across the cancer continuum and to develop publication skills in oncology nurses.
期刊最新文献
Assessing and Treating Causes of Depressed Mood in Patients With Cancer. Bloodless Medicine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial. Confusing Genomic Terms: The Importance of Being Precise. Consistent Nursing Presence Through Questionably Unprecedented Times.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1